Prevention of relapse following cognitive therapy vs medications in moderate to severe depression

Archives of General Psychiatry

Volumn 62, Issue 4, 2005, Pages 417-422

  Hollon, Steven D ^a   DeRubeis, Robert J ^b   Shelton, Richard C ^a   Amsterdam, Jay D ^b   Salomon, Ronald M ^a   O'Reardon, John P ^b   Lovett, Margaret L ^a   Young, Paula R ^b   Haman, Kirsten L ^a   Freeman, Brent B ^b   Gallop, Robert ^c  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WEST CHESTER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; FOLLOW UP; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; OUTPATIENT DEPARTMENT; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; AMBULATORY CARE; ANTIDEPRESSIVE AGENTS; COGNITIVE THERAPY; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; NUTRITION SURVEYS; PAROXETINE; PATIENT DROPOUTS; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 20144389733     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.62.4.417     Document Type: Article

References (24)

1. Hollon SD, Thase ME, Markowitz JC. Treatment and prevention of depression. Psychol Sci Public Interest. 2002;3:39-77.
2. Hollon SD, Shelton RC. Treatment guidelines for major depressive disorder. Behav Ther. 2001;32:235-258.
3. Blackburn IM, Eunson KM, Bishop S. A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both. J Affect Disord. 1986;10:67-75.
4. Kovacs M, Rush AJ, Beck AT, Hollon SD. Depressed outpatients treated with cognitive therapy or pharmacotherapy: a one-year follow-up. Arch Gen Psychiatry. 1981;38:33-39.
5. Simons AD, Murphy GE, Levine JL, Wetzel RD. Cognitive therapy and pharmacotherapy for depression: sustained improvement over one year. Arch Gen Psychiatry. 1986;43:43-48.
6. Evans MO, Hollon SO, DeRubeis RJ, Piasecki JM, Grove WM, Garvey MJ, Tuason VB. Differential relapse following cognitive therapy and pharmacotherapy for depression. Arch Gen Psychiatry. 1992;49:802-808.
7. Shea MT, Elkin I, Imber SD, Sotsky SM, Watkins JT, Collins JF, Pilkonis PA, Beckham E, Glass DR, Dolan RT, Parloff MB. Course of depressive symptoms over follow-up: findings from the National Institute of Mental Health Treatment of Depression Collaborative Research Program. Arch Gen Psychiatry. 1992;49:782-787.
8. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry. 2000;157(4 suppl):1-45.
9. DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, O'Reardon JP, Lovett ML, Gladis MM, Brown LL, Gallop R. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry. 2005;62:409-416.
10. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen (SCID-I/P W/PSY SCREEN). New York: Biometrics Research, New York State Psychiatric Institute; 2001.
11. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62.
12. Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, Leber WR, Docherty JP, Fiester SJ, Parloff MB. NIMH Treatment of Depression Collaborative Research Program, I: general effectiveness of treatments. Arch Gen Psychiatry. 1989;46:971-982.
13. Spitzer RL, Williams JBW, Gibbon M, First MB. Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II, Version 1.0). Washington, DC: American Psychiatric Press; 1990.
14. Fawcett J, Epstein P, Fiester SJ, Elkin I, Autry JH. Clinical management: imipramine/placebo administration manual: NIMH Treatment of Depression Collaborative Research Program. Psychopharmacol Bull. 1987;23:309-324.
15. Reimherr FW, Amsterdam JD, Quitkin FM, Rosenbaum JF, Fava M, Zajecka J, Beasley CM, Michelson D, Roback P, Sundell K. Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry. 1998;155:1247-1253.
16. Keller MB, Lavori PW, Friedman B, Nielsen E, Endicott J, McDonald-Scott P, Andreasen NC. The longitudinal interval follow-up evaluation. Arch Gen Psychiatry. 1987;44:540-548.
17. Fleiss JL, Cohen J. Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons Inc; 1973.
18. Cox DR, Oakes D. Analysis of Survival Data. London, England: Chapman & Hall; 1984.
19. Collett D. Modeling Survival Data in Medical Research. New York, NY: Chapman & Hall; 1994.
20. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry. 1986;143:18-23.
21. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48:851-855.
22. Antonuccio DO, Thomas M, Danton WG. A cost-effectiveness analysis of cognitive behavior therapy and fluoxetine (Prozac) in the treatment of depression. Behav Ther. 1997;28:187-210.
23. Barber JP, DeRubeis RJ. On second thought: where the action is in cognitive therapy for depression. Cogn Ther Res. 1989;13:441-457.
24. Teasdale JD, Segal Z, Williams JMG. How does cognitive therapy prevent depressive relapse and why should attentional control (mindfulness) training help? Behav Res Ther. 1995;33:25-39.